AZN

AstraZeneca PLC

$186.03+0.70% today
AI Take · AlgoThesis

AstraZeneca's 28.3 P/E sits uncomfortably between growth and value territory while its RSI of 37 signals oversold conditions—yet the stock trades 5.8% below its 52-week peak. The disconnect suggests recent selling pressure despite fundamentals that justify a premium multiple for a large-cap pharma with blockbuster oncology and cardiovascular pipelines. A 0.11% short float offers minimal squeeze catalyst, but the depressed RSI combined with $316B market cap stability hints at institutional accumulation rather than panic. The current setup appears vulnerable to mean reversion upward, though execution risks on pipeline assets remain priced into the valuation.

Snapshot

Market cap
$316.4B
P/E
28.3
Forward P/E
17.2
EPS (TTM)
$6.65
Dividend yield
1.74%
Net margin
17.2%
ROE
22.3%
RSI (14)
37
Beta
0.76
Short % of float
0.1%
Days to cover
0.9
52w high
No

Recent headlines

Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
SeekingAlpha
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
Benzinga
Reported Earlier, AstraZeneca's TRUQAP Wins FDA Oncologic Drugs Advisory Committee Backing For PTEN-Deficient mHSPC; CAPItello-281 Shows 19% Risk Reduction In Disease Progression
Benzinga

Build a thesis around AZN

Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.

Open in AlgoThesis →
AZN — AstraZeneca PLC · 0.1% short · P/E 28.3 · AlgoThesis